modelMedroxyprogesteroneAndEs

Extends from Pharmacolibrary.Drugs.ATC.G.G03FB06.

Information

name:	MedroxyprogesteroneAndEstrogen
ATC code:	G03FB06
route:	oral
compartments:	1
dosage:	2.5	mg
volume of distribution:	62	L
clearance:	1.5	L/h
other parameters in model implementation

A combined hormone therapy used primarily for menopausal hormone replacement in women, usually containing medroxyprogesterone acetate and an estrogen (commonly conjugated estrogens or estradiol). Used to treat symptoms associated with menopause such as hot flashes and to prevent osteoporosis. Although still in use, its prescription has declined due to concerns over long-term safety, particularly thromboembolic and cancer risks.

Pharmacokinetics

No published pharmacokinetic models for the fixed combination under ATC G03FB06 have been found. Parameter estimates are inferred based on data for individual components (oral medroxyprogesterone acetate and oral estradiol/conjugated estrogen) in healthy adult women.

References

Garza-Flores, J, et al., & Perez-Palacios, G (1991). Long-acting hormonal contraceptives for women. The Journal of steroid biochemistry and molecular biology 40(4-6) 697–704. DOI:10.1016/0960-0760(91)90293-e PUBMED:https://pubmed.ncbi.nlm.nih.gov/1958567
Zhou, XF, et al., & Sang, GW (1998). Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women. Contraception 57(6) 405–411. DOI:10.1016/s0010-7824(98)00048-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/9693401
Cromie, MA, et al., & Wajszczuk, CP (2000). Comparative effects of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic) on lipid profiles. Investigators from the Lunelle Study Group. Contraception 61(1) 51–59. DOI:10.1016/s0010-7824(99)00114-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10745070

Parameters

Type	Name	Default	Description
Modelica.Units.SI.Mass	weight (from PK_1C)	75	patient weight (kg)
Modelica.Units.SI.SpecificVolume	VdPerKg (from PK_1C)	0.9	Volume of distribution (L/kg)
Modelica.Units.SI.MassFraction	F (from PK_1C)	0.8	bioavailiability (0-1)
Pharmacolibrary.Types.Clearance	Cl (from PK_1C)	20	clearance
Modelica.Units.SI.Time	adminTime (from PK_1C)	60	first administration time (s)
Modelica.Units.SI.Time	adminDuration (from PK_1C)	600	administration duration (s)
Modelica.Units.SI.Time	adminPeriod (from PK_1C)	86060	period of administration (default 8 hours)(s)
Pharmacolibrary.Types.Mass	adminMass (from PK_1C)	1000	administration mass (mg)
Integer	adminCount (from PK_1C)	8	number of dose administered (1)
Pharmacolibrary.Types.Volume	Vd (from PK_1C)	VdPerKg*weight	Volume of distribution (m3)
Pharmacolibrary.Types.MassConcentration	Cmin (from PK_1C)	0.004	minimal therapeutic range
Pharmacolibrary.Types.MassConcentration	Cmax (from PK_1C)	0.008	minimal therapeutic range
Pharmacolibrary.Types.MassConcentration	Ctox_peak (from PK_1C)	0.012	toxicity peak level
Pharmacolibrary.Types.MassConcentration	Ctox_trough (from PK_1C)	0.006	toxicity trough level
Pharmacolibrary.Types.TransferRate	ka (from PK_1C_enteral)	0.016666666666666666	first order absorption rate
Modelica.Units.SI.Time	Tlag (from PK_1C_enteral)	600	delay between oral administration and absorption (default 10min)

Connectors

Type	Name	Default	Description
Types.ConcentrationOutput	C_central (from PK_1C)
Interfaces.ConcentrationPort_b	centralCPort (from PK_1C)

Components

Type	Name	Description
Pharmacokinetic.NoPerfusedTissueCompartment	central (from PK_1C)
Pharmacokinetic.ClearanceDrivenElimination	elim (from PK_1C)
Sources.PeriodicDose	periodicDose (from PK_1C)
Modelica.Units.SI.Time	t1_2 (from PK_1C)	elimination half-life

Revisions

06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)